Novo Nordisk is working on a new obesity drug that could help ... Semaglutide, the GLP-1 drug that Novo sells under the brand ...

The new joint-society guidance may alleviate some of the uncertainty. Among the recommendations: Continuing GLP-1 RAs in the ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

The odds for aspiration is greatest in the first weeks after a GLP-1 med is prescribed, since the delay in stomach emptying ...

Losing weight on GLP-1 drugs like Ozempic isn't guaranteed. Experts reveal how to tell if yours isn't working and the next steps you should take to reach your weight loss goals.

For Sprackling, the key to consumers benefiting from GLP-1 medications is responsible use rather than viewing them as a quick ...

A new Northbrook pharma will work to bring its obesity treatment to market that it says holds advantages over Ozempic and its ...

Compounded GLP-1s for Weight Loss: What Are They and Are They Safe? GLP-1s (glucagon-like peptide-1 receptor agonists ... involves changing or adding new ingredients to a medication or combining ...